(Z)-9-(2-methoxybenzylidene)-2-nitro-9H-fluorene | 136036-58-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 英文名称: (Z)-9-(2-methoxybenzylidene)-2-nitro-9H-fluorene
• 英文别名: 2-(2-nitro-fluoren-9-ylidenemethyl)-anisole；2-Nitro-9-(2-methoxy-benzyliden)-fluoren；2-(2-Nitro-fluoren-9-ylidenmethyl)-anisol；(9Z)-9-[(2-methoxyphenyl)methylidene]-2-nitrofluorene
• CAS: 136036-58-3
• 化学式: C₂₁H₁₅NO₃
• 分子量: 329.355
• InChiKey: LIVLGIRFBZKJEV-UNOMPAQXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.17
• 重原子数：
  25.0
• 可旋转键数：
  3.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  52.37
• 氢给体数：
  0.0
• 氢受体数：
  3.0

反应信息

• 作为产物：
  描述：

  2-硝基芴 、 邻甲氧基苯甲醛 在 二(4-甲氧基苯基)氧化碲(IV) 作用下， 以 乙腈 为溶剂， 反应 1.0h， 以80%的产率得到(Z)-9-(2-methoxybenzylidene)-2-nitro-9H-fluorene
  参考文献：
  名称：

  Ultrasonicated Condensation of Indene and 2-Nitrofluorene with Aromatic Aldehydes Catalyzed bybis-(pMethoxyphenyl)telluroxide (BMPTO)

  摘要：

  The condensation of indene or 2-nitrofluorene with aromatic aldehydes catalyzed by bis-(p-methoxyphenyl)telluroxide (BMPTO) under ultrasonic wave irradiation gave corresponding fulvenes in fair to good yield.

  DOI：

  10.1080/00397919708004087

文献信息

• [EN] BAX AGONIST, COMPOSITIONS, AND METHODS RELATED THERETO<br/>[FR] AGONISTE DE BAX, COMPOSITIONS ET PROCÉDÉS ASSOCIÉS
  申请人：UNIV EMORY

  公开号：WO2013028543A1

  公开（公告）日：2013-02-28

  The disclosure relates to BAX activators and therapeutic uses relates thereto. In certain embodiments, the disclosure relates to methods of treating or preventing cancer, such as lung cancer, comprising administering a therapeutically effective amount of a pharmaceutical composition comprising a compound disclosed herein or pharmaceutically acceptable salt to a subject in need thereof.

  本公开涉及BAX激活剂及其治疗用途。在某些实施例中，本公开涉及治疗或预防癌症的方法，例如肺癌，包括向需要的受试者施用本公开的化合物或药学上可接受的盐所述的药物组合的治疗有效量。
• BAX AGONIST, COMPOSITIONS, AND METHODS RELATED THERETO
  申请人：Deng Xingming

  公开号：US20140178374A1

  公开（公告）日：2014-06-26

  The disclosure relates to BAX activators and therapeutic uses relates thereto. In certain embodiments, the disclosure relates to methods of treating or preventing cancer, such as lung cancer, comprising administering a therapeutically effective amount of a pharmaceutical composition comprising a compound disclosed herein or pharmaceutically acceptable salt to a subject in need thereof.

  该披露涉及BAX活化剂及其治疗用途。在某些实施例中，该披露涉及治疗或预防癌症的方法，例如肺癌，包括向需要该治疗的受试者施用含有此处披露的化合物或药学上可接受的盐的药物组合物的治疗有效量。
• Structure-activity relationship studies on Bax activator SMBA1 for the treatment of ER-positive and triple-negative breast cancer
  作者：Gang Liu、Tao Yin、Hyejin Kim、Chunyong Ding、Zhuo Yu、Hong Wang、Haiying Chen、Ruping Yan、Eric A. Wold、Hao Zou、Xi Liu、Ye Ding、Qiang Shen、Jia Zhou

  DOI：10.1016/j.ejmech.2019.06.004

  日期：2019.9

  In an effort to develop novel Bax activators for breast cancer treatment, a series of diverse analogues have been designed and synthesized based on lead compound SMBA1 through several strategies, including introducing various alkylamino side chains to have a deeper access to S184 pocket, replacing carbon atoms with nitrogen, and reducing the nitro group of 9H-fluorene scaffold. Compounds 14 (CYD-2-11) and 49 (CYD-4-61) have been identified to exhibit significantly improved antiproliferative activity compared to SMBA1, with IC50 values of 3.22 mu M and 0.07 mu M against triple-negative breast cancer MDA-MB-231 and 3.81 mu M and 0.06 mu M against ER-positive breast cancer MCF-7 cell lines, respectively. Mechanism of action studies of compound 49 indicated that it can activate Bax protein to induce cytochrome c release and regulate apoptotic biomarkers, leading to cancer cell apoptosis. Further in vivo efficacy studies of compounds 14 and 49 in nude mice bearing MDA-MB-231 tumor xenografts demonstrated that these drug candidates can significantly suppress tumor growth, indicating their therapeutic potential for the treatment of breast cancer. (C) 2019 Elsevier Masson SAS. All rights reserved.
• US9040567B2
  申请人：——

  公开号：US9040567B2

  公开（公告）日：2015-05-26
• US9402850B2
  申请人：——

  公开号：US9402850B2

  公开（公告）日：2016-08-02